July 11, 2024 01:39 PM EDT

Illumina competitor Element Biosciences raises $277M in Series D

Jared Whitlock

Features Editor

Element Biosciences has raised an additional $277 million in private financing to support commercialization of its benchtop DNA sequencer and an instrument launch as the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Illumina competitor Element Biosciences raises $277M in Series D

Jared Whitlock

Features Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Il­lu­mi­na com­peti­tor El­e­ment Bio­sciences rais­es $277M in Se­ries D

Features Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Illumina competitor Element Biosciences raises $277M in Series D